{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:36:14Z","timestamp":1789814174318,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T00:00:00Z","timestamp":1450224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2013R1A1A2A100005494"],"award-info":[{"award-number":["NRF-2013R1A1A2A100005494"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"crossref","award":["6-2014-0138"],"award-info":[{"award-number":["6-2014-0138"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s10495-015-1208-z","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T13:50:29Z","timestamp":1450273829000},"page":"351-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells"],"prefix":"10.1007","volume":"21","author":[{"given":"Zhezhu","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyeon","family":"Je","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae J.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Hang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,16]]},"reference":[{"key":"1208_CR1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/1078-0432.CCR-07-2247","volume":"14","author":"MP Kim","year":"2008","unstructured":"Kim MP, Gallick GE (2008) Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res: Off J Am Assoc Cancer Res 14:1284\u20131285","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"1208_CR2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/14737140.8.4.511","volume":"8","author":"A Hilbig","year":"2008","unstructured":"Hilbig A, Oettle H (2008) Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Rev Anticancer Ther 8:511\u2013523","journal-title":"Expert Rev Anticancer Ther"},{"key":"1208_CR3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605\u20131617","journal-title":"N Engl J Med"},{"key":"1208_CR4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1517\/14728222.2011.566216","volume":"15","author":"J Long","year":"2011","unstructured":"Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C et al (2011) Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 15:817\u2013828","journal-title":"Expert Opin Ther Targets"},{"key":"1208_CR5","doi-asserted-by":"crossref","unstructured":"Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J et al (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Nat Cancer Inst 107:dju413","DOI":"10.1093\/jnci\/dju413"},{"key":"1208_CR6","doi-asserted-by":"crossref","first-page":"8255","DOI":"10.18632\/oncotarget.3143","volume":"6","author":"G Lo Re","year":"2015","unstructured":"Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F (2015) Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget 6:8255\u20138260","journal-title":"Oncotarget"},{"key":"1208_CR7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","volume":"3","author":"G Ambrosini","year":"1997","unstructured":"Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917\u2013921","journal-title":"Nat Med"},{"key":"1208_CR8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymthe.2004.05.006","volume":"10","author":"H Uchida","year":"2004","unstructured":"Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y et al (2004) Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther: J Am Soc Gene Ther 10:162\u2013171","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"1208_CR9","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/onc.2008.303","volume":"27","author":"DC Altieri","year":"2008","unstructured":"Altieri DC (2008) New wirings in the survivin networks. Oncogene 27:6276\u20136284","journal-title":"Oncogene"},{"key":"1208_CR10","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jpedsurg.2006.04.020","volume":"41","author":"T Azuhata","year":"2006","unstructured":"Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD (2006) Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg 41:1431\u20131440","journal-title":"J Pediatr Surg"},{"key":"1208_CR11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/med.21264","volume":"33","author":"JR Kanwar","year":"2013","unstructured":"Kanwar JR, Kamalapuram SK, Kanwar RK (2013) Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev 33:765\u2013789","journal-title":"Med Res Rev"},{"key":"1208_CR12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10620-008-0329-4","volume":"54","author":"WS Liu","year":"2009","unstructured":"Liu WS, Yan HJ, Qin RY, Tian R, Wang M, Jiang JX et al (2009) siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci 54:89\u201396","journal-title":"Dig Dis Sci"},{"key":"1208_CR13","first-page":"1681","volume":"32","author":"DH Yoon","year":"2012","unstructured":"Yoon DH, Shin JS, Jin DH, Hong SW, Jung KA, Kim SM et al (2012) The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Res 32:1681\u20131688","journal-title":"Anticancer Res"},{"key":"1208_CR14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","volume":"8","author":"DC Altieri","year":"2008","unstructured":"Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61\u201370","journal-title":"Nat Rev Cancer"},{"key":"1208_CR15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/cgt.2009.68","volume":"17","author":"R Zhang","year":"2010","unstructured":"Zhang R, Ma L, Zheng M, Ren J, Wang T, Meng Y et al (2010) Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice. Cancer Gene Ther 17:275\u2013288","journal-title":"Cancer Gene Ther"},{"key":"1208_CR16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4161\/cbt.5.7.2893","volume":"5","author":"QX Li","year":"2006","unstructured":"Li QX, Zhao J, Liu JY, Jia LT, Huang HY, Xu YM et al (2006) Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther 5:860\u2013866","journal-title":"Cancer Biol Ther"},{"key":"1208_CR17","doi-asserted-by":"crossref","first-page":"11177","DOI":"10.1074\/jbc.273.18.11177","volume":"273","author":"G Ambrosini","year":"1998","unstructured":"Ambrosini G, Adida C, Sirugo G, Altieri DC (1998) Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273:11177\u201311182","journal-title":"J Biol Chem"},{"key":"1208_CR18","first-page":"2805","volume":"60","author":"RA Olie","year":"2000","unstructured":"Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA et al (2000) A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805\u20132809","journal-title":"Cancer Res"},{"key":"1208_CR19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0214891","volume":"109","author":"M Pennati","year":"2002","unstructured":"Pennati M, Colella G, Folini M, Citti L, Daidone MG, Zaffaroni N (2002) Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Investig 109:285\u2013286","journal-title":"J Clin Investig"},{"key":"1208_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-9966-28-81","volume":"28","author":"W Shen","year":"2009","unstructured":"Shen W, Wang CY, Wang XH, Fu ZX (2009) Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 28:81","journal-title":"J Exp Clin Cancer Res"},{"key":"1208_CR21","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-06-4257","volume":"67","author":"AB Kunnumakkara","year":"2007","unstructured":"Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853\u20133861","journal-title":"Cancer Res"},{"key":"1208_CR22","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","volume":"22","author":"S Wang","year":"2003","unstructured":"Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628\u20138633","journal-title":"Oncogene"},{"key":"1208_CR23","doi-asserted-by":"crossref","first-page":"e10376","DOI":"10.1371\/journal.pone.0010376","volume":"5","author":"J Kauh","year":"2010","unstructured":"Kauh J, Fan S, Xia M, Yue P, Yang L, Khuri FR et al (2010) c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS ONE 5:e10376","journal-title":"PLoS ONE"},{"key":"1208_CR24","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/sj.onc.1205258","volume":"21","author":"S Fulda","year":"2002","unstructured":"Fulda S, Meyer E, Debatin KM (2002) Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21:2283\u20132294","journal-title":"Oncogene"},{"key":"1208_CR25","first-page":"393","volume":"4","author":"H Zhu","year":"2005","unstructured":"Zhu H, Guo W, Zhang L, Davis JJ, Wu S, Teraishi F et al (2005) Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther 4:393\u2013397","journal-title":"Cancer Biol Ther"},{"key":"1208_CR26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","volume":"12","author":"L Zhang","year":"2005","unstructured":"Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228\u2013237","journal-title":"Cancer Gene Ther"},{"key":"1208_CR27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.113.204743","volume":"346","author":"DR Premkumar","year":"2013","unstructured":"Premkumar DR, Jane EP, Foster KA, Pollack IF (2013) Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther 346:201\u2013210","journal-title":"J Pharmacol Exp Ther"},{"key":"1208_CR28","first-page":"1247","volume":"6","author":"SQ He","year":"2007","unstructured":"He SQ, Rehman H, Gong MG, Zhao YZ, Huang ZY, Li CH et al (2007) Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest. Cancer Biol Ther 6:1247\u20131257","journal-title":"Cancer Biol Ther"},{"key":"1208_CR29","first-page":"251","volume":"23","author":"ZW Xu","year":"2003","unstructured":"Xu ZW, Kleeff J, Friess H, Buchler MW, Solioz M (2003) Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 23:251\u2013258","journal-title":"Anticancer Res"},{"key":"1208_CR30","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1007\/s13277-014-1787-2","volume":"35","author":"L Mao","year":"2014","unstructured":"Mao L, Yang C, Li L, Nai L, Fan L, Wang J et al (2014) Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells. Tumour Biol: J Int Soc Oncodev Biol Med 35:5937\u20135944","journal-title":"Tumour Biol: J Int Soc Oncodev Biol Med"},{"key":"1208_CR31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3727\/096504013X13793555706722","volume":"21","author":"J Yang","year":"2013","unstructured":"Yang J, Ouyang J, Ouyang L, Ouyang L, Chen Y (2013) Inhibition of cell proliferation and increase of chemosensitivity by simultaneous knockdown of XIAP and survivin in pancreatic carcinoma cells. Oncol Res 21:43\u201350","journal-title":"Oncol Res"},{"key":"1208_CR32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ijc.22619","volume":"121","author":"M Retzer-Lidl","year":"2007","unstructured":"Retzer-Lidl M, Schmid RM, Schneider G (2007) Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer 121:66\u201375","journal-title":"Int J Cancer"},{"key":"1208_CR33","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3892\/ijo.2013.1812","volume":"42","author":"SY Kim","year":"2013","unstructured":"Kim SY, Kang S, Song JJ, Kim JH (2013) The effectiveness of the oncolytic activity induced by Ad5\/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy. Int J Oncol 42:1337\u20131348","journal-title":"Int J Oncol"},{"key":"1208_CR34","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1074\/jbc.274.4.2072","volume":"274","author":"DW Seol","year":"1999","unstructured":"Seol DW, Billiar TR (1999) A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem 274:2072\u20132076","journal-title":"J Biol Chem"},{"key":"1208_CR35","first-page":"523","volume":"18","author":"JW Seol","year":"2007","unstructured":"Seol JW, Chaudhari AA, Lee YJ, Kang HS, Kim IS, Kim NS et al (2007) Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep 18:523\u2013529","journal-title":"Oncol Rep"},{"key":"1208_CR36","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1158\/1535-7163.MCT-10-0370","volume":"9","author":"NV Rajeshkumar","year":"2010","unstructured":"Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, Lopez-Rios F, Fujiwara K, Matsui WH et al (2010) A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 9:2582\u20132592","journal-title":"Mol Cancer Ther"},{"key":"1208_CR37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.canlet.2010.10.015","volume":"332","author":"A Arlt","year":"2013","unstructured":"Arlt A, Muerkoster SS, Schafer H (2013) Targeting apoptosis pathways in pancreatic cancer. Cancer Lett 332:346\u2013358","journal-title":"Cancer Lett"},{"key":"1208_CR38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00006676-200107000-00011","volume":"23","author":"SM Ibrahim","year":"2001","unstructured":"Ibrahim SM, Ringel J, Schmidt C, Ringel B, Muller P, Koczan D et al (2001) Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 23:72\u201379","journal-title":"Pancreas"},{"key":"1208_CR39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/B978-0-12-398342-8.00004-5","volume":"115","author":"R Alemany","year":"2012","unstructured":"Alemany R (2012) Chapter four-design of improved oncolytic adenoviruses. Adv Cancer Res 115:93\u2013114","journal-title":"Adv Cancer Res"},{"key":"1208_CR40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12094-012-0951-7","volume":"15","author":"R Alemany","year":"2013","unstructured":"Alemany R (2013) Viruses in cancer treatment. Clin Trans Oncol: Offl Publ Fed Span Oncol Soc Nat Cancer Inst Mexico 15:182\u2013188","journal-title":"Clin Trans Oncol: Offl Publ Fed Span Oncol Soc Nat Cancer Inst Mexico"},{"key":"1208_CR41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/157488509788185123","volume":"4","author":"A Sharma","year":"2009","unstructured":"Sharma A, Tandon M, Bangari DS, Mittal SK (2009) Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther 4:117\u2013138","journal-title":"Curr Drug Ther"},{"key":"1208_CR42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbrc.2014.09.107","volume":"453","author":"S Kang","year":"2014","unstructured":"Kang S, Kim JH, Kim SY, Kang D, Je S, Song JJ (2014) Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus. Biochem Biophys Res Commun 453:480\u2013485","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-015-1208-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-015-1208-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-015-1208-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T06:26:53Z","timestamp":1589610413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-015-1208-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,16]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1007\/s10495-015-1208-z","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,16]]}}}